^
    2d
    A Comparative Evaluation of Pharmacokinetics and Immunogenicity. (clinicaltrials.gov)
    P1, N=180, Completed, Kashiv BioSciences, LLC | Active, not recruiting --> Completed | Trial primary completion date: Feb 2025 --> May 2025
    Trial completion • Trial primary completion date
    8d
    Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing (clinicaltrials.gov)
    P1, N=18, Completed, Xiamen Amoytop Biotech Co., Ltd. | Recruiting --> Completed | N=30 --> 18 | Trial primary completion date: Aug 2025 --> Jan 2026
    Trial completion • Enrollment change • Trial primary completion date
    |
    IL4 (Interleukin 4)
    9d
    An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Yonsei University
    New trial
    |
    carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Neulasta (pegfilgrastim)
    26d
    BRIA-ABC: Combination Study of SV-BR-1-GM With Retifanlimab (clinicaltrials.gov)
    P1/2, N=36, Completed, BriaCell Therapeutics Corporation | Enrolling by invitation --> Completed | Trial completion date: Nov 2028 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PGR positive
    |
    cyclophosphamide • Zynyz (retifanlimab-dlwr) • Bria-IMT (SV-BR-1-GM)
    29d
    Poly-Infections in a Patient Living With Human Immunodeficiency Virus (HIV). (PubMed, Cureus)
    Bone marrow examination combined with genetic and molecular testing revealed a diagnosis of T-cell large granular lymphocytic leukemia (T-LGL), which explained the lack of response to tbo-filgrastim...Undiagnosed T-LGL may present with gram-negative bacteremia and failure to respond to granulocyte colony-stimulating factor (G-CSF), and Strongyloides infection should be considered in immunocompromised patients who are being evaluated for occult malignancy, even without identifiable epidemiological risk factors. Early recognition of these conditions can guide timely evaluation and appropriate therapy in complex immunocompromised hosts.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    Neupogen (filgrastim)
    2ms
    RP2-001-18: Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Replimune Inc. | Trial completion date: Apr 2028 --> Oct 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • First-in-human
    |
    Opdivo (nivolumab) • sturlimogene erparepvec (RP2)
    2ms
    GCSF-PAIN: G-CSF-Induced Bone Pain and Supportive Care Approaches (clinicaltrials.gov)
    P=N/A, N=225, Completed, Ankara Etlik City Hospital | Recruiting --> Completed | N=128 --> 225
    Trial completion • Enrollment change
    |
    Neulasta (pegfilgrastim) • Lonquex (lipegfilgrastim) • Neupogen (filgrastim)
    2ms
    Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults (clinicaltrials.gov)
    P1, N=180, Completed, Kashiv BioSciences, LLC
    New P1 trial
    2ms
    RPL-123-01: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (2025-521621-33-00)
    P4, N=41, Not yet recruiting, Replimune Group Inc.
    New P4 trial
    |
    RP3 • Tudriqev (vusolimogene oderparepvec-wtpg) • sturlimogene erparepvec (RP2)
    2ms
    From Aortitis to Sweet's: The Immune Spectrum of G-CSF Adverse Events. (PubMed, Semin Arthritis Rheum)
    Exogenous G-CSF can precipitate a coherent spectrum of immune-mediated toxicity with distinct, clinically actionable timing windows: vascular events peak 7-15 days after pegfilgrastim, whereas cutaneous, articular, and pulmonary manifestations arise within 2-7 days. Recognition hinges on temporal linkage, imaging/histology, and exclusion of mimics. Management is phenotype-aware-drug withdrawal ± short glucocorticoids, formulation switching for CPPD, and targeted IL-6 blockade in selected refractory aortitis-allowing preservation of hematologic benefits while minimizing immune toxicity. Prospective surveillance and structured re-exposure studies (including formulation tailoring) are priorities to move from signal detection to prevention.
    Review • Journal • Adverse events
    |
    CSF2 (Colony stimulating factor 2)
    |
    Neulasta (pegfilgrastim)
    3ms
    RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC (clinicaltrials.gov)
    P2, N=5, Terminated, Replimune Inc. | Trial completion date: Mar 2027 --> Aug 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Aug 2025; Business reasons.
    Trial completion date • Trial termination • Trial primary completion date • Mismatch repair • pMMR
    |
    EGFR (Epidermal growth factor receptor)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • RP3 • sturlimogene erparepvec (RP2)
    3ms
    An Open-label, Single-arm, Exploratory Clinical Study to Evaluate the Efficacy and Safety of mecapegfilgrastim in Preventing Chemotherapy-Induced Neutropenia in Patients with Breast Cancer (ChiCTR2600116027)
    P2, N=48, Not yet recruiting, Beijing Cancer Hospital; Beijing Cancer Hospital
    New P2 trial
    |
    HHPG-19K (mecapegfilgrastim)